a Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA;
b DLH Corporation, Atlanta, GA;
cPhiladelphia Department of Public Health, Philadelphia, PA;
d Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, MA;
eYale University School of Medicine, New Haven, CT; and
f Connecticut Department of Public Health, Hartford, CT.
Correspondence to: Jesse O'Shea, MD, Centers for Disease Control and Prevention, Division of HIV Prevention, 1600 Clifton Rd, MS E-45, Atlanta, GA 30329 (e-mail: [email protected]).
This work was supported by the Division of HIV Prevention, Centers for Disease Control and Prevention Research gGrant FOA PS14-001(ClinicalTrials.gov, NCT02693145). The 3 grantees were Philadelphia Department of Public Health, Massachusetts Department of Public Health, and Connecticut Department of Public Health. The funders participated in the study design, data collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
The authors have declared that no competing interests exist.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).
